TCT-16
Do overlapping scaffolds have an impact on clinical outcome? Analysis of the ABSORB-EXTEND single arm study
Pieter C. Smits,1 Alexandre Abizaid2
1Maasstad Hospital Rotterdam, Rotterdam, Netherlands; 2Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

BACKGROUND Pre-clinical data show that overlapping scaffold segments show delayed healing and strut coverage compared to non-overlapping scaffold segments. Little is known whether this may have an impact on clinical outcome.

METHODS Within the ABSORB-EXTEND study of 812 patients with 1 year follow-up complete, patients with overlapping scaffolds (n=115) were compared to patients with non-overlapping scaffolds (n=659).

RESULTS No differences in baseline patient and lesion characteristics between both patient groups were noted, apart from the significant longer lesion length in the overlapping scaffold group (16.7±7.3 versus 11.6±4.4 mm, p<0.0001; 95% CI: 3.7-6.4) and subsequently less lesion type B1 and more B2. Furthermore, more patients were treated for stable angina in the overlapping scaffold group (72% versus 54%, p=0.0003). The overlapping scaffold group showed 61.1% (33/55) of the lesions were >20 mm long, compared to 33/734 (5%) lesions in the non-overlapping group, p<0.0001. The 1 year clinical outcome is summarized in the table below. Scaffold Thrombosis is reported according ARC and Myocardial Infarction according protocol definitions.

<table>
<thead>
<tr>
<th>Cardiac death</th>
<th>Myocardial Infarction (MI)</th>
<th>Q wave MI</th>
<th>non-Q wave MI</th>
<th>Target Lesion Revascularization</th>
<th>Def/Prob Scaffold Thrombosis (ST)</th>
<th>Early Def/Prob ST</th>
<th>Late Def/Prob ST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overlapping</td>
<td>0.9%</td>
<td>8.7%</td>
<td>1.7%</td>
<td>7.0%</td>
<td>0.9%</td>
<td>1.7%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Non-overlapping</td>
<td>0.7%</td>
<td>2.4%</td>
<td>0.9%</td>
<td>1.6%</td>
<td>0.3%</td>
<td>0.3%</td>
<td>0.4%</td>
</tr>
<tr>
<td>P value</td>
<td>0.6</td>
<td>0.002</td>
<td>0.9</td>
<td>0.003</td>
<td>0.6</td>
<td>0.1</td>
<td>1.0</td>
</tr>
</tbody>
</table>

CONCLUSIONS In the non to moderate complex lesion population of ABSORB-EXTEND, patients with overlapping scaffolds showed only significantly more non-Q wave myocardial infarctions compared to the non-overlapping scaffold group. This difference occurred mainly in-hospital and was procedure related.

CATEGORIES CORONARY: Stents: Bioresorbable Vascular Scaffolds

KEYWORDS Bioabsorbable scaffolds, Long lesion treatment, PCI - Percutaneous Coronary Intervention

TCT-17
Prospective, Multi-Center Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and 3-Year Clinical and Imaging Results
Stefan Verheye,1 Joachim Schofer,2 Michael Maeng,3 Bernhard Wittenbi cher,4 Roberto Botelho,5 John A. Ormiston,6 Ricardo Calvo,1 Jose A. Damia,1 Juliana P. Castro,1 Andrea Abizaid,1 Yan Joan,1 Vinayak Bhat,1 Lynn Morrison,1 Sara Toylov,1 Alexandre Abizaid1
1Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium; 2Medical Care Center Prof Mathey, Prof Schofer, Hamburg University Cardiovascular Center, Hamburg, Germany; 3Aarhus University Hospital, Aarhus, Denmark; 4Helios Amper-Klinikum Dachau, Berlin, Germany; 5Triangulo Heart Institute, Uberlândia, Brazil; 6Professor, University of Auckland Medical School, Auckland, New Zealand; 7INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA, SAO PAULO, Brazil; 8Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil; 9Cardiovascular Research Center, Sao Paulo, Sao Paulo; 10Elixir Medical Corporation, Sunnyvale, CA; 11elixir medical corporation, Sunnyvale, CA; 12Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

BACKGROUND The DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System (NEBCSS) is a drug-eluting bioresorbable scaffold combining a PLLA-based scaffold coated with Novolimus, a macrocyclic lactone mTOR inhibitor with potent anti-proliferative properties. The drug dose is 5 μg per mm of scaffold length; the device is available in multiple diameters (2.5 - 3.5 mm) and lengths (14, 18 and 28 mm). The DESolveNx study is multi-center evaluation of the safety and efficacy of the DESolve NEBCSS in patients with single, de novo, native coronary artery lesions.

METHODS A total of 126 patients were enrolled in this prospective registry. Patients receiving the study device were analyzed for multiple clinical endpoints including: device and procedure success; Major Adverse Cardiac Events (MACE), a composite endpoint of cardiac death, target vessel MI, or clinically-indicated target lesion revascularization (CI-TLR); Target Vessel Revascularization, (CI-TV R) and stent thrombosis assessed at 1, 6 and annually. Patients underwent angiographic assessment at 6 months and a subset of patients underwent IVUS and OCT assessment also at 6 months and imaging 12 months using multislice computed tomography (MSCT). Additionally, at single centers, multi-modality imaging was completed at 18 months and 3 years.

RESULTS Mean age at baseline was 62 years, 32% were females, and 21% diabetics. Lesion length was 11.2 mm, RVD was 3.06 mm, and 18.3% showed moderate-to-heavy calcification. Six-month QCA demonstrated low mean in-scaffold late lumen loss (0.20 mm), 18.3% DS and an MLD of 2.45 mm, Serial IVUS at baseline and 6 months demonstrated a significant increase in mean lumen (Δ 10.0%, p = < 0.001) and scaffold areas (Δ 15.7%, p = < 0.001) with 98.8% neointimal coverage of the scaffold at 6 months. Twelve-month MSCT results demonstrated lumen dimension maintenance from 6 to 12 months. QCA at 18 months shows minimal lumen change and 3 year OCT imaging reveals the “golden tube” indicating resorption of the scaffold. Clinical events remained low (MACE = 5.69% and 7.4% at 12 and 24 months respectively) with no reports of definite stent thrombosis.

CONCLUSIONS DESolve demonstrated safety and efficacy with low late lumen loss. Serial imaging assessments indicated early vessel restoration at 6 months with good luminal patency at 12 months by MSCT. At 12 and 24 months, the clinical event rates remain low. Imaging endpoints at 18 months and 3 years and 3-year clinical results will be presented.

CATEGORIES CORONARY: Stents: Bioresorbable Vascular Scaffolds

KEYWORDS Bioabsorbable scaffolds, Drug-eluting stent, bioabsorbable, Novolimus

TCT-18
Impact of Incomplete Revascularization after Percutaneous Coronary Intervention as Assessed by the SYNTAX Revascularization Index in Complex Coronary Artery Disease: A SEEDS Substudy
Nicolas Bettinger,1 Changdong Guan,2 Yuejin Yang,3 Martin Leon,4 Bo Xu,1 Philippe Genereux5
1NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY; 2Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, China; 3Cardiovascular Institute and Piuwai Hospital, National Center for Cardiovases, Beijing, China; 4Cardiovascular Research Foundation, New York, United States; 5Columbia University Medical Center, New York

BACKGROUND The SYNTAX revascularization index (SRI), representing the percentage of revascularized myocardium, has been shown to be a strong independent predictor of adverse ischemic events after percutaneous coronary intervention (PCI); however, its predictive capability among patients with complex coronary artery disease (CAD) undergoing PCI with second-generation everolimus eluting stents remains to 5 years. All explored. We sought to evaluate the impact of incomplete revascularization as assessed by the SRI on 2-year adverse ischemic events in a population of patients with complex CAD undergoing EES-PCI.

METHODS Among 1900 patients enrolled in A Registry to Evaluate Safety and Effectiveness of Everolimus Drug Eluting Stent for Coronary Revascularization (SEEDS), SRI was available in 1851. Patients were stratified into three groups (SRI<100%, SRI 100 to 99%, and SRI <50%), according to the proportion of revascularized myocardium. Mortality and major adverse cardiac events (MACE) were compared between groups.

Abstract nos: 18 - 25

Complex and Higher-Risk Indicated Patients

Tuesday, October, 13, 2015, 2:00 PM-4:00 PM
RESULTS Among the 1851 patients, the mean SRI was 85.4 ± 23.4%, ranging from 4% to 100%. Complete revascularization (SRI=100%) was achieved in 64.3% of patients, SRI= 50-99% in 472 patients (25.5%), and SRI <50% in 189 patients (10.2%). The 2-year rates of mortality (0.4%, 1.9%, and 2.7%, p < 0.001) and MACE (6.0%, 11.4%, and 10.1%, p > 0.001) were higher in patients with lower SRI. By ROC analysis, an SRI cut-off of 85% showed the best prognostic accuracy for 2-year mortality. A SRI of >85% had similar low all-cause death and cardiac death rates when compared to complete SRI=100% revascularization (Figure). By multivariable analysis, SRI was a strong predictor of 2-year mortality (HR: 4.20, 95% CI: 1.46-12.08, p = 0.008) and 2-year MACE (HR: 1.59, 95% CI: 1.14-2.23, p = 0.007).

CONCLUSIONS In patients with complex CAD undergoing EES-PCI, the SRI was identified as a strong predictor of 2-years mortality and MACE. Given its correlation with mortality, the SRI may be useful in assessing the degree of revascularization after PCI, with SRI >85% as a reasonable goal.

BACKGROUND High-risk percutaneous coronary intervention (PCI) supported by percutaneous left ventricular assist devices offers a treatment option for patients with severe symptoms, complex and extensive coronary artery disease (CAD), and multiple comorbidities. The extrapolation from clinical trial to real-world practice has inherent uncertainties. We compared the characteristics, procedures, and outcomes of high-risk PCI supported by a microaxial pump (Impella 2.5) in a multicenter registry vs. the randomized PROTECT II trial (NCT00562016).

METHODS The USpella registry is an observational multicenter voluntary registry of Impella technology in 47 sites in the United States and 2 sites in Canada. A total of 637 patients undergoing high-risk PCI supported by Impella 2.5 between 6/2007 and 9/2013 were included in this analysis. Of them, 330 patients would have met enrollment criteria for the PROTECT II trial. Baseline variables, procedural characteristics, and in-hospital outcomes of these registry patients were compared with 216 patients treated in the Impella arm of the PROTECT II trial. All events were centrally adjudicated by an independent clinical events committee.

RESULTS Compared to the clinical trial, registry patients were older (70±11.5 vs. 67.5±11.0 years), more likely to have chronic kidney disease (30% vs. 22.7%), prior myocardial infarction (69.3% vs. 56.5%), prior by-pass surgery (39.4% vs. 30.2%), and had similar prevalences of diabetes, peripheral vascular disease, and prior stroke. Registry patients had more extensive CAD (2.2 vs. 1.8 diseased vessels), and had a similar SRS predicted risk of mortality (6.0% vs. 6.0 vs. 5.8% vs. 6.0, p = 0.64). Left ventricular ejection fraction was 23.4±6.3% and 21.5±7.7%, in the registry and clinical trial, respectively (p = 0.004). Use of rotational atherectomy was similar (16.4% vs. 14.8%, p = 0.63), but the number of passes per lesion was significantly higher.